Trial Profile
Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Alcoholic liver disorders
- Focus Therapeutic Use
- 08 Nov 2022 Results investigating if self-reported alcohol intake and blood phosphatidyl-ethanol are predictive of changes in liver histology and clinical outcomes in patients with early compensated ALD ,presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 03 Mar 2022 Status changed from recruiting to completed.
- 05 Jan 2015 New trial record